Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled date : 2022 - 01 - 06 save search
Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
Published: 2022-01-06 (Crawled : 23:00) - globenewswire.com
IOVA 4 | $11.69 -1.43% -1.45% 2.7M
|
Health Technology
|
| O: 1.56%
H: 4.66%
C: -0.12%
health thc conference therapeutics j.p. morgan healthcare conference iot
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference
Published: 2022-01-06 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.452 -1.72% -1.75% 91K
|
Professional, Scientific, and T...
|
| O: 2.75%
H: 0.0%
C: -7.25%
conference therapeutics
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
Published: 2022-01-06 (Crawled : 20:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 32.65%
H: 1.15%
C: -23.85%
flt201 new drug fda clearance application drug disease fda clearance
Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder
Published: 2022-01-06 (Crawled : 20:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 0.64%
H: 3.48%
C: -2.53%
fin-211 order patent granted therapeutics ism
Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022
Published: 2022-01-06 (Crawled : 19:00) - biospace.com/
BTTX | $0.006 -65.02% 340K
|
|
| O: -2.66%
H: 8.0%
C: 5.47%
therapeutics
Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133Phase 1 data at projected efficacious dose (400 mg) indicate insufficient activity against hepatitis B virus to justify further development
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
ALGS | $0.8204 -0.39% -0.39% 640K
|
Health Technology
|
| O: -36.85%
H: 0.0%
C: -31.49%
alg-0101 hepatitis drug phase 1
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
ZYME | $8.555 -0.06% -0.06% 590K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -8.52%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.5%
H: 1.27%
C: 0.94%
xb002 drug license therapeutics antibody
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
Published: 2022-01-06 (Crawled : 14:30) - biospace.com/
APRE | $5.37 6.3% 6.3K
|
Health Technology
|
| O: -0.28%
H: 4.09%
C: -3.89%
health thc conference therapeutics j.p. morgan healthcare conference
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
Published: 2022-01-06 (Crawled : 14:30) - biospace.com/
BOLT | $1.19 7.21% 6.72% 150K
|
|
| O: -4.05%
H: 2.98%
C: -7.2%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -1.17%
H: 0.11%
C: -0.39%
bdc-1001 opdivo treatment solid tumors ongoing trial therapeutics 100 phase 1 iot her2- her2 nivolumab
i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules
Published: 2022-01-06 (Crawled : 14:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.75%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
ces research liver therapeutics collaboration
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.23%
H: 4.5%
C: 3.11%
health thc conference therapeutics j.p. morgan healthcare conference
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
NTLA | $21.16 -1.72% -1.75% 860K
|
Health Technology
|
| O: -0.35%
H: 3.81%
C: 1.53%
therapeutics intel milestone
Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
ARTH | $1.14 -17.78% 320
|
Manufacturing
|
| O: 0.0%
H: 0.92%
C: 0.92%
ac5 system therapeutics
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
XLO | $1.06 0.95% 0.94% 300K
|
Professional, Scientific, and T...
|
| O: 0.33%
H: 5.33%
C: -4.47%
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -2.58%
H: 1.2%
C: 0.05%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: 0.0%
LEGN | News | $45.205 -4.73% -4.97% 1.1M
|
Health Technology
|
| O: -7.55%
H: 3.65%
C: 3.07%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.96%
H: 0.58%
C: -0.12%
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -0.56%
H: 2.27%
C: -4.25%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.64%
H: 0.67%
C: 0.01%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.35%
H: 4.23%
C: 3.03%
therapeutics
Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 0.21%
H: 1.74%
C: -2.09%
ceo therapeutics
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
Published: 2022-01-06 (Crawled : 13:30) - biospace.com/
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 26.61%
H: 17.14%
C: 5.71%
alzheimer parkinson patent granted therapeutics disease neurodegenerative alzheimer’s grant alzheimer's
GBT Announces New Employment Inducement Grants
Published: 2022-01-06 (Crawled : 13:30) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 0.07%
H: 3.88%
C: 2.6%
granted grant
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
Published: 2022-01-06 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.75%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: -12.32%
H: 11.95%
C: 9.37%
sar4451 disease cel
First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Published: 2021-12-13 (Crawled : 13:27) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 0.24%
H: 3.2%
C: 0.42%
ath434 phase 2 trial authorization
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Published: 2022-01-04 (Crawled : 13:27) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 1.65%
H: 5.5%
C: 1.97%
conference therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.